JNJ logo

JNJ Johnson & Johnson

$264.74
$2.83
(1.06%)
Today
Closed $264.74
$0.26
(0.10%)
After Hours
42

Bearish Sentiment

How do you feel about JNJ?

Loading...
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High
Key PointsJohnson & Johnson has a deep and diversified pharmaceutical portfolio...
Nasdaq News: Markets
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Zacks
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are mostly bullish after positive Tremfya and Carvykti data.read more...
Benzinga
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $267.66, marking a -1.58% move from the previous day.
Zacks
Defensive Dividends: 3 Companies Investors Can Rely On
Several members of the elite Dividend Kings club, including JNJ, KO, and ABBV, are known for dividend reliability, each with a long, consistent history of increasing payouts. The trio boasts a strong defensive nature given consumers' needs for their products no matter the backdrop.
Zacks
Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss
Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.read more...
Benzinga
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis (gMG) Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with...
PR Newswire
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.
Zacks